Compare · NTR vs NXTS
NTR vs NXTS
Side-by-side comparison of Nutrien Ltd. (NTR) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTR and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- NTR is the larger of the two at $32.43B, about 8636.5x NXTS ($3.8M).
- Over the past year, NTR is up 11.3% and NXTS is down 92.4% - NTR leads by 103.7 points.
- NTR has been more active in the news (7 items in the past 4 weeks vs 2 for NXTS).
- NTR has more recent analyst coverage (25 ratings vs 0 for NXTS).
PerformanceNTR+11.31%NXTS-92.40%
2025-06-09+0.00%2026-06-08
- Company
- Nutrien Ltd.
- Nexentis Technologies Inc.
- Price
- $67.30+0.15%
- $5.38-15.01%
- Market cap
- $32.43B
- $3.8M
- 1M return
- -1.58%
- -4.95%
- 1Y return
- +11.31%
- -92.40%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 7
- 2
- Recent ratings
- 25
- 0
NTR
Nutrien Ltd.
Nutrien Ltd. provides crop inputs, services, and solutions. The company offers potash, nitrogen, phosphate, and sulfate products; and financial solutions. It also distributes crop nutrients, crop protection products, seeds, and merchandise products through approximately 2,000 retail locations in the United States, Canada, South America, and Australia. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada.
Latest NTR
- SEC Form 6-K filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- SEC Form SUPPL filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- Nutrien Prices Offering of an Aggregate of US$1.0 Billion of 5-Year and 10-Year Senior Notes
- SEC Form FWP filed by Nutrien Ltd.
- SEC Form SUPPL filed by Nutrien Ltd.
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- Nutrien Announces Mark Thompson as a Speaker at the BMO Farm to Market Conference
- SEC Form 6-K filed by Nutrien Ltd.
Latest NXTS
- Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
- Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX's Algorithm Platform MITOLINE™
- Nexentis Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form S-3 filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders
- SEC Form 10-K filed by Nexentis Technologies Inc.